title: [Type 2 diabetes in France: epidemiology, trends of medical care, social and economic burden].
abstract: Between 2001 and 2007, treatments for type 2 diabetes have increased and therapeutic choices have improved. However glycemic control remains insufficient. Cardiovascular risk control has widely increased. Statins, hypertensive and antithrombotic treatments are more often prescribed. Blood pressure and LDL cholesterol levels have decreased whatever age. However, progress remains possible, especially regarding blood pressure control. Obesity has increased between 2001 and 2007 to reach 41% whereas the frequency of dietetic visits has decreased. Insulin therapy (more than obesity) determines the frequency of dietetic visits: dietetic care happens too late. Important improvements of the quality of follow-up are observed. However, fundus exams and more specifically albuminuria measurement remain insufficiently performed and their progression is too slow, as well as the podiatric examination. Only 10% of people with type 2 diabetes have an endocrinology visit, which has been stable between 2001 and 2007. Information expectations of people with type 2 diabetes are strong, especially for diet. Education demand is lower but more important for people who have already benefited. This improvement of medical care leads to an increase in the cost of reimbursements. The consequences of diabetes, more than the disease itself, alter the quality of life.
authors.affiliation: Institut de veille sanitaire, 94415 Saint-Maurice, France. c.druet@invs.sante.fr
authors.forename: Céline
authors.initials: C
authors.lastname: Druet
authors.forename: Isabelle
authors.initials: I
authors.lastname: Bourdel-Marchasson
authors.forename: Alain
authors.initials: A
authors.lastname: Weill
authors.forename: Eveline
authors.initials: E
authors.lastname: Eschwege
authors.forename: Alfred
authors.initials: A
authors.lastname: Penfornis
authors.forename: Sandrine
authors.initials: S
authors.lastname: Fosse
authors.forename: Cécile
authors.initials: C
authors.lastname: Fournier
authors.forename: Michèle
authors.initials: M
authors.lastname: Chantry
authors.forename: Claude
authors.initials: C
authors.lastname: Attali
authors.forename: Pierre
authors.initials: P
authors.lastname: Lecomte
authors.forename: Dominique
authors.initials: D
authors.lastname: Simon
authors.forename: Nathalie
authors.initials: N
authors.lastname: Poutignat
authors.forename: Arnaud
authors.initials: A
authors.lastname: Gautier
authors.forename: Mathilde
authors.initials: M
authors.lastname: Risse
authors.forename: Anne
authors.initials: A
authors.lastname: Fagot-Campagna
mesh_terms: D000924:Anticholesteremic Agents / Q000191:economics / Q000627:therapeutic use; D000959:Antihypertensive Agents / Q000191:economics / Q000627:therapeutic use; D002318:Cardiovascular Diseases / Q000188:drug therapy / Q000191:economics / Q000209:etiology / Q000517:prevention & control; D015897:Comorbidity; D017281:Cost of Illness; D003924:Diabetes Mellitus, Type 2 / Q000150:complications / Q000178:diet therapy / Q000188:drug therapy / Q000191:economics / Q000453:epidemiology*; D017719:Diabetic Foot / Q000517:prevention & control; D003928:Diabetic Nephropathies / Q000175:diagnosis / Q000517:prevention & control; D004046:Dietetics; D019468:Disease Management; D004363:Drug Utilization; D004704:Endocrinology; D005602:France / Q000453:epidemiology; D017048:Health Care Costs; D006801:Humans; D007004:Hypoglycemic Agents / Q000191:economics / Q000627:therapeutic use; D007328:Insulin / Q000627:therapeutic use; D009765:Obesity / Q000178:diet therapy / Q000453:epidemiology; D010353:Patient Education as Topic; D011788:Quality of Life; D012017:Referral and Consultation / Q000706:statistics & numerical data; D012306:Risk
chemical_list: D000924:Anticholesteremic Agents; D000959:Antihypertensive Agents; D007004:Hypoglycemic Agents; D007328:Insulin